Anti-tumor necrosis factor (anti-TNF) agents have revolutionized the treatment of CD, allowing control of intestinal inflammation and, consequently, preventing or at least delaying progressive intestinal damage and its harmful consequences, such as the development of strictures, fistulas and abscesses [8, 9]. Here, TNF is linked to abscess.